Major Depressive Disorder (MDD)
Conditions
Keywords
oxytocin, psychedelics, lsd, psilocybin, Depression
Brief summary
This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.
Interventions
None listed
Sponsors
University of Geneva, Switzerland
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>=18 years-old * MDD defined by DSM-V criteria, and resistant to treatment * Ongoing classical psychotherapeutic treatment * Agreement to discontinue necessary psychotropic medications (some classes of anti-depressants are allowed with no need to taper off).
Exclusion criteria
* Psychotic or bipolar disorder * High suicidal risk * Severe cardiovascular, hepatic or neurological (affecting the central nervous system) disorders * Pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Salivary Oxytocin | One day | Measure taken during psychedelic treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Beck Depression Inventory | 3 months | Self-reported depressive symptoms |
| Cognitive Flexibility Inventory | 3 months | Self-reported flexibility questionnaire |
| Trait anxiety inventory (STAI-T) | 3 months | Self-reported anxiety symptoms |
| Cognitive Emotion Regulation Questionnaire (CERQ) | 3 months | Self-reported cognitive emotion regulation strategies |
| Emotion Regulation Questionnaire | 3 months | self-reported emotion regulation strategies |
Countries
Switzerland
Outcome results
None listed